Quartz
์ค๋ ์ฑํฅ
๊ธฐํ
๊ธ์ ์ Tango Therapeutics stock surges on pancreatic cancer drug combo data
A combination of vopimetostat and Revolution Medicines' daraxonrasib produced a 92% response rate in patients with advanced pancreatic cancer
๋ด์ค
๐บ๐ธ ๋ฏธ๊ตญ ยท "DARAXONRASIB" ยท ์ด 7๊ฑด
ํํฐ ๋ณด๊ธฐ๋ด์ค ์ฌ๋ฆฌ ์ง์๊ท ํ49์์ธ โพ
๊ท ํ
49ํ์ฌ ์ง์
48.8
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
๊ทน๋จ ๋ถ์ ๋ถ์ ์ค๋ฆฝ๊ธ์ ๊ทน๋จ ๊ธ์
์ต๊ทผ 7์ผ ๊ธฐ์ค 10,988๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 48.8(๊ท ํ)์ ๋๋ค. ๊ธ์ 1,134๊ฑด(10.3%)ยท์ค๋ฆฝ 7,805๊ฑด(71.0%)ยท๋ถ์ 2,049๊ฑด(18.6%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 22.5(๋ณด์ ๊ฒฝํฅ)์ ๋๋ค.
๊ธ์ 1,134
์ค๋ฆฝ 7,805
๋ถ์ 2,049
๋ณด์ ๊ฒฝํฅ
๋ฏธ๋์ด ์ฑํฅ๋ณด์ ๊ฒฝํฅ ยท 22.5
์ง๋ณด ์ฑํฅ์ค๋ ์ฑํฅ๋ณด์ ์ฑํฅ
L 1,936 ยท C 3,331 ยท R 4,025
๋
์ ๋ฐ์ ์ฑํฅํ๋ณธ ๋ถ์กฑ ยท 0.0
์ง๋ณด ์ฑํฅ์ค๋ ์ฑํฅ๋ณด์ ์ฑํฅ
ํ๋ณธ 0๊ฑด (L 0 ยท C 0 ยท R 0)
์ข
ํฉ ์ฑํฅ๋ณด์ ๊ฒฝํฅ ยท 22.5
์ง๋ณด ์ฑํฅ์ค๋ ์ฑํฅ๋ณด์ ์ฑํฅ
ํ์๋ผ์ธ ํค์๋
์ต๊ทผ 24์๊ฐ
The Conversation (US)
์ค๋ ์ฑํฅ
๊ธฐํ
๊ธ์ ์ Breakthrough drug nearly doubles survival with advanced pancreatic cancer โ an oncologist explains how daraxonrasib overcame an โundruggableโ disease
Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these tumors so deadly.
NBC News Top Stories
์ง๋ณด ์ฑํฅ
๊ธฐํ
๊ธ์ ์ Breakthrough pancreatic cancer treatment could double survival time
A new study on a groundbreaking pancreatic cancer drug finds that it has the potential to double survival rates for more than 90 percent of patients. Researchers are now exploring whether the drug, called daraxonrasib, could also be effective in lung, ovarian, and colorectal cancers. NBC Newsโ Erika Edwards reports.
Fortune
์ค๋ ์ฑํฅ
๊ธฐํ
๊ธ์ ์ Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. โI actually started cryingโ
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases โ a target that had eluded treatment for decades.
CBS News
์ง๋ณด ์ฑํฅ
๊ธฐํ
New drug nearly doubles survival rates in some pancreatic cancer patients, study says
New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.
NBC News Top Stories
์ง๋ณด ์ฑํฅ
๊ธฐํ
After new drugโs โunprecedentedโ results for pancreatic cancer, doctors look at other uses
The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.
PBS NewsHour
์ค๋ ์ฑํฅ
๊ธฐํ
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
1 / 1 (์ด 7๊ฑด)